Glaukos Corp

Latest Report Overview

Glaukos Corp (GKOS) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $186 million with diluted EPS of $-0.31 and net income of $-18 million. Operating margin was -8.5%, and free cash flow was $12 million for the period.

Key Takeaways for Glaukos Corp

• Revenue growth accelerated to 49.5% YoY in Q2 2026 to $185.6 million, evidencing strong market penetration of the iStent product line.
• Gross margins remain exceptionally high at 81.7%, showcasing the company's ability to command premium pricing through technological differentiation.
• Operating losses persist as the company aggressively allocates capital towards R&D ($51.3M in Q2) and marketing to maintain its competitive moat.
• The company maintains a solid cash position of $114.5 million, providing runway for continued clinical trial execution and product commercialization.
• Surgeon training requirements act as a significant barrier to entry, effectively creating switching costs that secure the company's market position against lower-cost alternatives.

What Does Glaukos Corp Do?

Glaukos Corp is an ophthalmic medical technology company that develops and commercializes innovative solutions for the treatment of glaucoma, corneal disorders, and retinal diseases. Its product portfolio is anchored by its proprietary micro-invasive glaucoma surgery (MIGS) technologies, primarily the iStent family, which are designed to reduce intraocular pressure for patients with glaucoma. The company also offers a suite of corneal health solutions, including corneal cross-linking therapies and specialized devices. The company serves a global customer base of ophthalmologists and surgeons, primarily operating in the United States and international markets. Glaukos differentiates itself through a model that combines high-tech device innovation with rigorous physician training, ensuring that surgeons are deeply familiar with the company's specific product ecosystem. This integration makes Glaukos a foundational player in the ophthalmology vertical, emphasizing quality-of-care and precision outcomes over mass-market volume strategies.

Growth Drivers for Glaukos Corp

• Continued adoption of iStent products in glaucoma surgery, serving as the primary growth engine.
• Geographic expansion into emerging international markets to increase the addressable patient population.
• Pipeline development in the retina and corneal health segments, providing diversification beyond traditional glaucoma products.
• Strategic physician training and education programs designed to accelerate the transition to minimally invasive surgical procedures.
• New product launches that improve patient outcomes and potentially expand reimbursement coverage.